Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Avibactam/ceftazidime

Development of resistance

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Arns B, et al. Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime-avibactam: A prospective multicentric cohort study. Journal of Global Antimicrobial Resistance 36 : 393-398, Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.jgar.2024.02.001 Arns B, et al. Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime-avibactam: A prospective multicentric cohort study. Journal of Global Antimicrobial Resistance 36 : 393-398, Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.jgar.2024.02.001
Metadaten
Titel
Avibactam/ceftazidime
Development of resistance
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55977-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Propofol

Case report

Minoxidil